StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultAug 5, 2026, 04:15 PM

Teknova Q2 Revenue $12.2M, up 18%; Raises 2026 Guidance

AI Summary

Alpha Teknova, Inc. reported strong financial results for the second quarter ended June 30, 2026, with total revenue increasing 18% year-over-year to $12.2 million. The company also announced an improved net loss and significantly reduced Free Cash Outflow. Following these results, Teknova raised its full-year 2026 revenue guidance to $45-47 million and adjusted its Free Cash Outflow expectations to less than $8 million. Additionally, the company launched its proprietary AI-powered Build-TekTM custom order configurator.

Key Highlights

  • Total revenue for Q2 2026 was $12.2 million, an 18% increase from Q2 2025.
  • Lab Essentials revenue grew 18% to $9.2 million in Q2 2026.
  • Clinical Solutions revenue increased 18% to $2.4 million in Q2 2026.
  • Gross margin improved to 40.1% in Q2 2026, up from 38.7% in Q2 2025.
  • Net loss for Q2 2026 was $(3.2) million, or $(0.06) per diluted share.
  • Adjusted EBITDA for Q2 2026 was $(0.7) million, an improvement from $(0.8) million.
  • Free Cash Outflow significantly improved to $(0.6) million in Q2 2026.
  • Company raised 2026 revenue guidance to $45-47 million and expects Free Cash Outflow less than $8 million.